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Tumor microenvironments play crucial roles in cancer initiation and progression, 
and share many molecular and pathological features with the wound healing 
process. In contrast with wounds that heal within a limited timeframe, tumors do 
not heal in the absence of treatment. Wounds heal through the coordination of a 
myriad of cell types, including endothelial cells, leukocytes, and fibroblasts. 
Similar sets of cells also contribute to cancer initiation and progression; 
consequently, anti-cancer treatment strategies that target endothelial cells and/or 
leukocytes have been proposed and tested. Less attention, however, has been paid 
to the roles of cancer-associated fibroblasts (CAFs). The heterogeneity of fibroblasts 
present in tumor tissues hinders the elucidation of their roles in tumor initiation 
and progression at the cellular and molecular levels. In this review, we discuss the 
origin of CAFs and their crucial roles in cancer initiation and progression, as well 
as the possibility of developing a novel type of anti-cancer treatment through 





Dvorak proposed that tumors are wounds that do not heal[1], based on his 
discovery of vascular endothelial growth factor (VEGF). VGEF is produced in 
wound healing and at tumor sites[2], and can account for chronic 
hyperpermeability-mediated fibrin deposition in solid tumors and in the early 
stages of wound healing[3]. Moreover, solid tumors and the wound healing process 
share many pathological and molecular features. 
Irrespective of the cause and the severity of wounds, healing proceeds to repair 
the structure and functions of injured organs and tissues, through a series of 
processes; hemostasis, humoral inflammation with microvascular permeability and 
extravascular clotting, cellular inflammation with inflammatory cell infiltration, 
angiogenesis, and generation of mature connective tissue stroma[4]. These steps 
proceed through interaction between parenchymal cells and the stroma, a complex 
mixture of inflammatory cells, matrix proteins, and tissue cells such as fibroblasts 
and endothelial cells. In the case of acute and mild wounds, injured organs and 
tissues are completely replaced by proliferating parenchymal cells, but if not 
replenished completely, they are filled with connective tissue. Tumor cells, 
regardless of their site of origin, behave like parenchymal cells in normal tissues 
and proliferate by interacting with the stroma[4]. 
Fibroblasts are a major cell type within the stroma and contribute to tissue 
remodeling in development and tissue homeostasis by providing structural 
scaffolding and growth regulatory mediators. Moreover, following tissue injury, 
fibroblasts exhibit an activated and contractile phenotype with enhanced 
expression of α-smooth muscle actin (α-SMA) and are referred to as 
myofibroblasts[5]. Myofibroblasts synthesize increased amount of various collagens 
and extracellular matrix proteins (ECM) to provide a scaffold and to eventually aid 
in wound repair[5]. Furthermore, the cells are important sources of many growth 
factors and cytokines that regulate wound healing processes[6]. 
Under co-culture conditions, primary normal fibroblasts isolated from various 
human tissues can restrict in vitro proliferation of various types of human cancer 
cell lines[7]. Indeed, if Nod-like receptor pyrin domain-containing protein 6 
(NLRP6) is absent in fibroblasts within the stem cell niche of the colon, 
regeneration of the colonic mucosa and the processes of epithelial proliferation and 
migration are impaired. Consequently, colitis-associated tumorigenesis is 
accelerated in mice lacking NLRP6[8]. Thus, under normal conditions, fibroblasts 
work as a sentinel cell to maintain epithelial tissue homeostasis and to prevent the 
initiation of tumorigenesis in the colon, in an NLRP6-dependent manner. 
Like fibroblasts in the wound healing process, fibroblasts present in tumor 
tissues exhibit an activated and myofibroblast-like phenotype with α-SMA 
expression and are referred to as cancer-associated fibroblasts (CAFs)[9]. In contrast 
to fibroblasts in normal tissues, CAFs in most solid tumors are presumed to 
promote tumor development and progression by providing cancer cells with a 
myriad of growth factors[9,10]. However, in pancreatic ductal cancer, CAFs can 
deliver immune stimulating signals. As a result, depletion of CAFs induces 
immunosuppression with increased intra-tumoral regulatory T cells (Tregs) and 
eventually accelerates tumor progression with reduced survival[11]. Hence, the 
pathophysiological roles of CAFs in the development and progression of solid 
tumors are yet to be elucidated. 
We will herein discuss the pathophysiological roles of CAFs and their clinical 
relevance in cancer, and specifically in colorectal cancer (CRC).  
 
CAFS IN COLITIS-ASSOCIATED COLON CARCINOGENESIS MODEL 
Accumulating evidence highlights the crucial contribution of chronic inflammation 
to tumor development and progression[12]. Colitis-associated colon carcinogenesis 
(CAC) is a typical example of this pathological process. CAC frequently ensues 
from chronic intestinal inflammatory changes observed in patients with 
inflammatory bowel diseases such as ulcerative colitis (UC), particularly those 
with a long duration, extensive involvement, and severe inflammation[13]. 
Pathological features of UC include mucosal damage and ulceration with 
prominent leukocyte infiltration, firstly involving the rectum and extending 
proximally. 
Oral administration of dextran sulfate sodium (DSS) solution to rodents can 
cause acute inflammatory reactions and ulceration in the entire colon, similar to 
that observed in human patients with UC; therefore, it is widely used to reproduce 
human UC[14]. Moreover, repeated DSS ingestion can lead to the development of a 
small number of colon carcinomas in approximately 50% of mice[15], suggesting 
that the inflammatory response alone can cause colon carcinoma. The incidence of 
DSS-induced colon carcinogenesis is both increased and accelerated by a prior 
administration of azoxymethane (AOM)[16], which can alone cause colon cancer by 
inducing O6-methyl guanine formation and mutations of the β-catenin gene[17]. 
Thus, combined treatment with AOM and DSS is frequently used to recapitulate 
the molecular mechanisms underlying CAC. 
The NF-ĸB transcription factor is a key player in inflammation. NF-ĸB activity is 
triggered by the IĸB kinase (IKK) complex in response to a wide variety of 
pro-inflammatory stimuli such as infectious agents and pro-inflammatory 
cytokines[18]. Greten and colleagues demonstrated that IKKβ has crucial roles in 
AOM/DSS-induced CAC through two distinct pathways: prevention of epithelial 
cell apoptosis, and enhancement of myeloid cell growth factor expression[19]. These 
observations indicate the crucial involvement of inflammatory cell infiltration in 
CAC development. Given the crucial roles of NF-ĸB in the regulation of gene 
expression and the biological functions of pro-inflammatory cytokines such as 
tumor necrosis factor (TNF)-α and chemokines[18], we examined 
AOM/DSS-induced colon carcinogenesis process using mice deficient in the tumor 
necrosis factor receptor (TNF-R)p55 gene[20]. We revealed that genetic ablation of 
the TNF-Rp55 gene in myeloid cells resulted in reduced intracolonic infiltration of 
inflammatory cells, particularly macrophages, neovascularization, and subsequent 
tumor formation. Moreover, a TNF-inhibitor reduced tumor progression even 
when administered after multiple tumors had developed in the colon. Similar 
phenotypes were observed by genetic inactivation of a macrophage-tropic 
chemokine receptor gene, CCR2, in myeloid cells or following the administration of 
CCR2 inhibitors after multiple colon tumors developed[21]. 
These observations prompted us to examine the roles of another 
macrophage-tropic chemokine, CCL3, and its receptors, CCR1 and CCR5[22]. Mice 
deficient in CCL3, CCR1, or CCR5, displayed marginal inflammatory reactions and 
subsequently developed few colon tumors when AOM was administered together 
with 3% DSS ingestion. Wild-type (WT) mice failed to survive 4.5% DSS ingestion. 
Mice deficient in CCL3, CCR1, or CCR5 mice survived 4.5% DSS ingestion and 
displayed prominent mucosal damage and leukocyte infiltration in the colon. 
CCR1-deficient mice developed multiple colon tumors; however, the same 
treatment resulted in a small number of colon tumors in CCL3- or CCR5-deficient 
mice (Table 1)[22]. These observations indicate that inflammatory cell infiltration is 
necessary, but not sufficient, for the development of CAC in this model. 
Compared with WT or CCR1-deficient mice, CCL3- or CCR5-deficient mice 
exhibited reduced accumulation of CAFs in the colon. This accumulation was 
predominantly evident in the later phase of CAC in this model (Table 1). Several 
groups, including ours, further demonstrated that growth factors such as 
hepatocyte growth factor (HGF)[23], epiregulin[24], and heparin-binding epidermal 
growth factor-like growth factor (HB-EGF)[22] are highly expressed in CAFs. These 
growth factors promote tumor cell proliferation in the later phase of this CAC 
model. Moreover, deficiency of the CCR5 gene results in reduced growth of tumors 
arising from either subcutaneous or orthotopic intracecum injection of a syngeneic 
mouse colon adenocarcinoma cell line, colon 26. This attenuated tumor growth was 
associated with a reduction in type I collagen-positive fibroblast numbers but not 
with inflammatory cell infiltration[22]. These observations indicate that CAFs are 
involved in the progression, but not development, of CAC. 
 
ORIGINS OF CAFS (FIGURE 1) 
The lack of a specific marker to identify CAFs[25] hampers the precise identification 
of their origin. α-SMA, a robust CAF marker, is also expressed by normal colonic 
fibroblasts under in vitro culture conditions[26] as well as other cell types such as 
pericytes, smooth muscle cells surrounding vasculature, and cardiomyocytes[27]. 
Additional candidate CAF markers including FAP-α[28,29], S100A4/fibroblast 
specific protein (FSP)-1[30,31], neuron-glial antigen-2, PDGF receptor-β, and prolyl 
4-hydroxylase[32]. However, these molecules are not specific to CAFs and can be 
expressed by other cell types. The lack of a definitive CAF marker implies that 
CAFs in CRC are phenotypically and functionally heterogeneous. This assumption 
is further strengthened by global gene expression profiles[33]. 
The most likely cellular source of CAFs in CRC is resident fibroblasts in colon 
tissues. Supporting this notion, CAFs in CRC liver metastatic foci exhibit similar 
protein expression pattern as resident liver fibroblasts[34]. Kojima and colleagues 
demonstrated that resident human mammary fibroblasts progressively convert 
into CAF-like cells with enhanced α-SMA expression and pro-tumorigenic capacity, 
during the course of tumor progression in a breast tumor xenograft model[35]. 
Moreover, these cells express transforming growth factor (TGF)-β and a chemokine, 
stromal-derived factor (SDF)-1/CXCL12, which further initiate and maintain the 
differentiation of fibroblasts into CAF-like and the tumor-promoting phenotype in 
an autocrine and amplifying manner[35]. 
In their quiescence state, stellate cells are vitamin A-containing and lipid 
droplet-containing cells and are present in various tissues including the liver, 
pancreas, kidney, and intestine[36]. Similar to CAFs, these cells activate α-SMA 
expression under inflammatory and oncogenic conditions, and acquire 
myofibroblast-like phenotypes. Most hepatocellular carcinomas arise in a cirrhotic 
liver with prominent fibrosis. Activated hepatic stellate cells are the major source 
of extracellular proteins during fibrogenesis. Moreover, they can induce 
hepatocellular carcinoma cell growth, neovascularization, and immune evasion, to 
promote tumor progression[37]. Similarly, pancreatic cancer is characterized by a 
prominent desmoplastic/stromal reaction. Like hepatic stellate cells, activated 
pancreatic stellate cells can abundantly produce the collagenous stroma of 
pancreatic cancer. Moreover, these cells can also interact closely with cancer cells to 
facilitate local tumor growth and distant metastasis, mediate angiogenesis, and 
induce immune evasion[38]. However, it has yet to be determined if stellate cells in 
the intestine, can also behave in a similar manner during colon carcinogenesis, as 
they do in the liver and pancreas. 
Other cell types are proposed to be a source of CAFs, based on the analyses of 
cancers other than CRC. Accumulating evidence indicates that, under chronic 
inflammatory conditions, epithelial cells can undergo epithelial-mesenchymal 
transition (EMT) to acquire myofibroblast-like phenotypes and participate in the 
synthesis of the fibrotic matrix[39]. A breast carcinoma biopsy provided evidence of 
EMT and a coincidental α-SMA-positive stromal reaction[40]. Moreover, upon 
injection of the MCF-7 mouse breast cancer cell line into nude mice with HBFL-1, a 
mammary gland epithelial cell line without tumorigenicity, HBFL-1 cells acquired 
myofibroblast-like phenotypes. In addition, a significant 3.5- to 7-fold increase in 
MCF-7 tumor size in nude mice was observed. Thus, breast cancer can transform 
its own non-malignant stroma to facilitate its growth[40]. Furthermore, when 
human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(EGFR-TKI)-resistant lung cancer cells were used as a xenograft model, 
EMT-derived tumor cells gave rise to about a quarter of CAFs, which provided 
cancer cells resistance to EGFR-TKI[41]. However, several independent groups 
argue against EMT as the origin of CAFs[42,43]. 
Bone marrow-derived mesenchymal stem cells (MSCs) have also been proposed 
as an origin of CAFs. MSCs and CAFs exhibit similar immunophenotypes and 
share the potential to differentiate into various cell lineages such as adipocytes, 
chondrocytes, and osteoblasts[44]. Fibrocytes are bone marrow-derived and 
circulating fibroblast progenitors and exhibit phenotypic and functional 
characteristics similar to CAFs in chemically induced rat breast carcinogenesis 
model[45], suggesting that fibrocytes can be an origin of CAFs. 
TGF-β1 can induce proliferating endothelial cells to undergo phenotypic 
conversion into fibroblast-like cells including the emergence of mesenchymal 
markers and reciprocal down-regulation of CD31[46]. When endothelial cells were 
irreversible tagged by crossing Tie2-Cre mice with R26Rosa-lox-Stop-lox-LacZ 
mice, endothelial-to-mesenchymal transition (EndMT) was evident at the invasive 
front of tumors in the B16F10 melanoma model and the Rip-Tag2 spontaneous 
pancreatic carcinoma model[46]. Choi and colleagues further demonstrated that 
endothelial heat shock protein (HSPB1, a synonym of HSP27 in humans and 
HSP25 in rodents) has a crucial role in the maintenance of endothelial phenotypes 
and that its deficiency mediates the EndMT to accelerate fibrosis, and eventually 
tumorigenesis, in lungs[47]. Smooth muscle cells can be another source of CAFs in 
several cancers, particularly prostate cancer. Normal prostate stroma is enriched in 
smooth muscle cells, but during prostatic carcinogenesis in rats and humans, 
smooth muscle cells disappear with the reciprocal appearance of CAFs, which can 
promote carcinogenesis in genetically abnormal but non-tumorigenic epithelial 
cells[48]. While smooth muscle cells may be a source of CAFs in prostate cancer, it is 
unclear whether CAFs originate from this population in other cancer types, 
particularly CRC. 
There is considerable evidence that indicates functional heterogeneity of CAFs in 
various cancers, including colon cancer[33]. Heterogeneity may arise from 
differences in the origin of CAFs. Alternatively, CAFs are generated by intricate 
interactions with tumor microenvironments consisting of cancer and other resident 
cells[10,25]. Therefore, the heterogeneity of tumor microenvironments can induce 
wide variation in CAFs. Nevertheless, the heterogeneity of CAFs can affect the 
clinical course of colon cancer patients[49]. 
 
RECRUITMENT AND ACTIVATION OF CAFS 
In chronic inflammation the chemokines CCL2 and CCL3 can recruit fibroblasts[50], 
while CXCL12[51], CCL21[52], and CCL3[53] can recruit fibrocytes. We have shown 
that CCL3 is produced locally at tumor sites and is associated with CAF 
accumulation[22,54]. Moreover, in a mouse gastric cancer model, a substantial 
proportion of CAFs originate from bone marrow-derived mesenchymal stem cells, 
which are recruited to tumor site in a TGF-β and CXCL12-dependent manner[55]. 
Therefore, CAF accumulation may be regulated by cooperation with chemokines 
and other fibroblast-tropic factors such as TGF-β. 
Normal fibroblasts can inhibit proliferation of cancer cells in vitro[7]. Moreover, 
normal intestinal fibroblasts can maintain epithelial homeostasis to prevent 
carcinogenesis[23]. Thus, malignant cells must reprogram normal fibroblasts into 
CAFs with pro-tumorigenic activity. This process is mediated by cancer 
cell-derived factors including TGF-β, CXCL12[35], platelet-derived growth factor 
(PDGF)[56], and interleukin (IL)-6[57]. In contrast, several lines of evidence indicate 
that the CAF phenotype can persist in the absence of continued exposure to cancer 
cell-derived factors[58]. This may be explained by the observation that CAFs 
increasingly acquire the capacity to express TGF-β and CXCL12, which can act to 
initiate and maintain differentiation into CAFs in an auto-stimulatory and 
cross-communicating manner[35]. Alternatively, CAFs may acquire irreversible 
genetic and/or epigenetic changes during the course of differentiation, as similarly 
observed on tumor endothelial cells[59]. 
 
CAFS IN CARCINOGENESIS 
Cancer cell growth and stemness (Figure 2) 
Human pre-malignant prostatic epithelial cells can transform to neoplastic cells 
when co-cultured with CAFs derived from human prostate cancer tissues in vitro[60]. 
Factors secreted from CAFs are believed responsible for this tumor-initiating 
capacity. Indeed, when human mammary epithelial cells are grafted into 
immunodeficient mice, together with fibroblasts overexpressing TGF-β and/or 
HGF, the engrafted cells develop into a proliferating tissue closely resembling 
human ductal carcinomas[61]. These observations raise the possibility that CAFs can 
initiate the malignant transformation of epithelial cells by secreting these growth 
factors. 
Under the influence of cancer cell-derived IL-6, CAFs can secrete 
metalloproteinases, to stimulate EMT and cancer stem cell phenotypes in prostate 
cancer[62]. CAFs in colon cancer secrete HGF, activate β-catenin-dependent 
transcription, and induce cancer stem cell clonogenicity[63]. Moreover, CAF-derived 
HGF also restores the cancer stem cell phenotype in more differentiated tumor 
cells both in vitro and in vivo. Furthermore, human colon cancer-derived and 
chemotherapy-treated CAFs abundantly produce IL-17A, which increases 
chemotherapy-resistant cancer stem cells[64]. 
CAFs produce various growth factors and cytokines, which can promote cancer 
cell proliferation: HGF[23], EGF[65], epiregulin[24], HB-EGF[22], insulin-like growth 
factor (IGF)[66], TGF-β[35], connective tissue growth factor (CTGF)[67], and CXC12[58]. 
Most of these growth factors can be produced by cancer cells and can enhance the 
growth of CAFs. Moreover, CAF-derived TGF-β and CXCL12 affect CAF 
proliferation in an autocrine dependent manner[35]. Thus, these growth factors 
form a positive feedback loop between cancer cells and CAFs, and may accelerate 
tumor progression. 
It is clear that CAFs can contribute to tumor development and progression by 
initiating malignant transformation, enhancing the proliferation of cancer cells, and 
inducing the cancer stem cell phenotype. 
 
Cancer cell migration, invasion, and metastasis (Figure 2) 
Wound healing assays performed in the presence of CAF-derived conditioned 
media show that colon cancer cell lines exhibit enhanced migratory ability, and 
increased clonogenic capacity compared with normal fibroblast-derived 
conditioned media[26]. Moreover, co-injection of CAFs with a human colon cancer 
cell line into nude mice, significantly increased tumor cell proliferation, compared 
with normal fibroblasts[26]. Gene ontology analysis further reveals that genes 
overexpressed in CAFs are associated with biological processes such as 
development (TGFB2, PDGFC, cMET, CADM1, WNT1) and cell-cell signaling 
(TFAP2C, NTF-3, SEMA5A, EFNB2, INHBA)[26]. These gene products can modulate 
the functions of cancer cells to promote invasion and metastasis. 
CAFs expressed various matrix metalloproteinases (MMPs) and MMP-mediated 
ECM degradation results in proteolytic destruction of basement membrane and 
aids tumor cells to invade surrounding tissues[68]. Moreover, MMP-mediated 
enhanced invasiveness also involves proteinase-activated receptor 1 (PAR1) 
expressed on the surface of cancer cells. CAF-derived MMP-1 cleaves PAR1 to 
activate PAR1-mediated signaling pathways, associated with cancer cell migration 
and invasion in cancer cells [69]. 
In the lung, fibroblasts and tumor cells abundantly produce CCL2, which 
recruits Gr-1-positive, CCR2-expressing inflammatory monocytes[70]. Recruited 
inflammatory monocytes subsequently instigate a pre-metastatic niche, which 
favors lung metastasis of mouse mammary cancer. A pre-metastatic niche can be 
formed by the direct actions of CAFs[71]. S100A4-positive CAFs abundantly 
produce VEGF-A, which plays an important role in the establishment of an 
angiogenic microenvironment at the metastatic site to facilitate colonization. 
Moreover, S100A4-positive CAFs produce tenascin-C to provide cancer cells with 
protection from apoptosis. 
Gene expression-based classification systems have identified an aggressive colon 
cancer subtype with mesenchymal features, possibly reflecting EMT of tumor cells. 
Comparative analysis of stromahigh and stromalow CRC shows that neoplastic cells 
in stromahigh tumors express specific EMT drivers including ZEB2, TWIST1, and 
TWIST2[72]. Moreover, type I collagen dominates the extracellular matrix in 
aggressive colon cancers with EMT markers. Mimicking the tumor 
microenvironment, Matrigel enriched with type I collagen can induce colon cancer 
cells to express tumor-specific mesenchymal genes; suppress expression of 
hepatocyte nuclear factor 4, a transcriptional activator of epithelial differentiation 
and its target genes; and invade patient-derived colon tumor organoids[72]. Thus, 
CAF-derived type I collagen can induce EMT in cancer cells to promote their 
invasion. 
Bone marrow-derived hematopoietic progenitor cells expressing VEGF receptor 
1 (VEGFR1) home to tumor-specific pre-metastatic sites[73]. Primary tumor-derived 
factors induce fibroblasts resident in pre-metastatic sites to express fibronectin, 
which interacts with VLA-4 on VEGFR1-positive cells to induce cell clusters and 
promote pre-metastatic niche formation. In fibroblasts, fibronectin expression is 
regulated by the sphingosine-1-phosphate (SIP)-SIP receptor-STAT3 pathway[74]. 
CAFs can activate the STAT3 pathway in cancer cells to promote malignant 
progression. CRCs frequently display elevated TGF-β production with mutational 
inactivation of the TGF-β pathway. Cancer cell-derived TGF-β stimulates CAFs to 
secrete IL-11, which triggers gp130/STAT3 signaling in tumor cells[75]. This 
cross-talk can provide metastatic cells with a survival advantage. 
 
Drug resistance 
CAF-derived ECM has a profound impact on cancer chemotherapy[76]. ECM forms 
a physical barrier and as a consequence, most anti-cancer drugs show limited 
penetration into solid tumors[77]. Moreover, after binding to ECM cancer cells 
acquire chemoresistance through the activation of various pro-survival signaling 
pathways including PI3K/Akt, Erk, Rho/Rock, and p53[76]. Adhesion of small cell 
lung cancer cells to ECM confers resistance to chemotherapeutic agents because the 
adhesion activates β1 integrin-stimulated tyrosine kinase to suppress 
chemotherapy-induced apoptosis[78]. Similar mechanisms may also work in the 
case of resistance to radiotherapy in glioma cells[79]. 
In addition to ECM, CAF-derived soluble factors have been demonstrated to be 
involved in drug resistance. CAF-derived CXCL12 mediates drug resistance to 
conventional chemotherapeutics[80]. This resistance can arise from the ability of 
CXCL12 to promote cancer cell survival by activating the focal adhesion kinases, 
Erk, and Akt, β-catenin and NF-ĸB, in CXCR4-expressing cancer cells[81]. 
The presence of driver mutations in receptor tyrosine kinase (RTK) pathways 
positions RTKs for potential targets for cancer therapy and, accordingly, many 
anti-cancer drugs have been developed targeting these RTKs[82]. RTK-mediated 
signals converge on common critical downstream cell-survival effectors such as 
PI3K and Erk. Consequently, most cells can be rescued from drug sensitivity by 
exposure to one or more unrelated RTK ligands. Among these RTK ligands, HGF 
confers resistance to the BRAF inhibitor in BRAF-mutant melanoma cells[83]. 
Likewise, CAF-derived HGF can confer the resistance to EGF-receptor inhibitors in 
human non-small cell lung cancer cells otherwise sensitive to inhibitors[84]. 
CRC initiating cells (CICs) are resistant to conventional chemotherapy in 
cell-autonomous assays, but CIC chemoresistance is also increased by CAFs. 
Comparative analysis of matched CRC specimens from patients before and after 
cytotoxic treatment revealed a significant increase in CAFs after cytotoxic 
treatment[64]. Chemotherapy-treated human CAFs promoted CIC self-renewal and 
in vivo tumor growth associated with increased secretion of specific cytokines and 
chemokines, including interleukin-17A (IL-17A). Exogenous IL-17A increased CIC 
self-renewal and invasion, and targeting IL-17A signaling impaired CIC growth. 
Notably, IL-17A was overexpressed by colorectal CAFs in response to 
chemotherapy and this observation was validated directly in patient-derived 
specimens without culture[64]. These data suggest that chemotherapy induces 
remodeling of the tumor microenvironment through activating CAFs to secrete 
cytokines such as IL-17. 
 
Tumor microenvironments (Figure 3) 
Chronic inflammation is closely associated with tumorigenesis of various types of 
cancer[12,85]. CAFs, a major cellular component of cancer-associated inflammation, 
mediate tumor-enhancing inflammation by expressing a pro-inflammatory gene 
signature in an NF-κB-dependent manner[86]. NF-ĸB activation enhanced the 
expression of several chemokines such as CCL2 and proinflammatory genes such 
as cyclooxygenase 2 (COX-2) in CAFs. CAF-derived CCL2 mediates the 
recruitment of blood monocytes to tumor sites[87], favoring the generation of 
tumor-associated macrophages with a potent pro-tumorigenic activity. 
Simultaneously, COX-2 generates prostaglandin E2, which can promote both 
normal and malignant colonic epithelial cell proliferation[88, 89]. 
Another prominent feature of CAFs is their ability to synthesize ECM, which can 
serve as a reservoir for various growth factors such as TGF-β, bFGF, PDGF, HGF, 
and IGF-1[90]. In response to mechanical stress in tumor tissues, CAFs exhibit an 
increase in contractility, which can augment the production of collagen[91]. 
Moreover, CAFs synthesize the specific ECM including type I collagen, oncofetal 
nectin splice variants, periostin, and hyaluronan, and remodel ECM to promote 
tumor growth[90]. CAFs also abundantly express lysyl oxidase (LOX), an enzyme 
responsible for cross-linking type I collagen. LOX-mediated cross-linking and 
resultant tumor tissue stiffness are associated with tumorigenesis[92]. Mechanical 
stress activates CAFs to express members of MMPs, which regulate the 
degradation of ECM[90]. MMP-mediated ECM degradation can also promote cancer 
cell invasion[68]. 
Tumor microenvironment is characterized by abundant neovascularization, 
which can be induced by CAFs. CAF-induced MMP activation degrades ECM and 
eventually causes neovascularization[68]. CAFs, particularly those in invasive 
margins, are a rich source of the CXC chemokine, SDF-1/CXCL12[58], which 
mediates the recruitment of endothelial progenitor cells (EPCs) and subsequent 
tumor neovascularization. Furthermore, hypoxia can induces CAFs to express the 
transcription factor, hypoxia-inducible factor (HIF)-1α, which in turn induces the 
expression of VEGF, a potent angiogenic factor[93]. VEGF production by CAFs can 
be further enhanced by CAF-derived IL-6, whose expression can be augmented in 
the presence of colon cancer cells[94]. 
 
Tumor immunity (Figure 4) 
Deletion of fibroblast activation protein (FAP)-positive stromal cells enhances 
tumor immunity[28] and provides direct evidence of the involvement of CAFs in 
suppressed tumor immunity. While several candidate mechanisms have been 
proposed, this study did not clarify the cellular and molecular mechanisms of 
CAFs involvement in suppressed tumor immunity. CAF-derived prostaglandin E2 
and indoleamine 2,3-dioxygenease (IDO) can inhibit natural killer (NK) cell 
functions, thereby contributing to immune escape and subsequent tumor 
progression[95]. CAF-derived tenascin also contributes to immune suppression at 
tumor sites. Soluble tenascin inhibits the proliferation of human T cells induced by 
the combination of anti-CD3 antibody and fibronectin. Tenascin further attenuates 
IL-2 driven T cell proliferation, and prevents induction of the IL-2 receptor at high 
levels[96]. Prostate cancer stem-like cells present in the draining lymph nodes use 
tenascin-C to inhibit T-cell receptor-dependent T-cell activation, proliferation, and 
cytokine production. Consequently, cancer stem-like cells are protected from T 
cell-mediated immune surveillance[97]. 
CAFs abundantly express TGF-β1, which can suppress the functions of various 
immune cells, particularly effector T cells and natural killer cells[98]. TGF-β 
regulates Treg maturation and thereby suppresses immune responses. VEGF is 
also produced by CAFs and exhibits immunosuppressive effects[99]. VEGF can 
suppress the maturation of dendritic cell precursors, promote the proliferation of 
Tregs, and the accumulation of myeloid-derived suppressor cells (MDSC) in 
peripheral immune organs, thereby inhibiting T-cell immune responses. 
In vivo vaccination with a DNA vaccine against FAP eliminates CAFs and causes 
a shift of the immune microenvironment from a Th2 to Th1 polarization. This shift 
is characterized by increased expression of IL-2 and IL-7, suppressed recruitment 
of tumor-associated macrophages (TAMs), MDSCs, and Tregs, and decreased 
tumor angiogenesis and lymphangiogenesis[100]. These observations suggest roles 
for CAFs in intratumor Th2 polarization and the subsequent depression of tumor 
immunity. Th2 polarization is mediated by CAF-derived thymic stromal 
lymphopoietin (TSLP), which induces in vitro myeloid DCs to up-regulate the 
TSLP receptor (TSLPR), secrete Th2-attracting chemokines, and acquire 
TSLP-dependent Th2-polarizing capability in vitro and in vivo[101]. Moreover, 
CD90-positive CAFs in colon cancer produce IL-6, which induces the polarization 
of tumor promoting inflammatory T helper 17 cells (Th17) in infiltrating 
lymphocytes, as well as the expression of cancer stem cell markers in colon cancer 
cells[102]. 
CAFs can produce a myriad of chemokines, which can attract and activate 
immunosuppressive cells, such as M2-polarized TAMs, MDSCs, and Tregs, 
thereby suppressing tumor immunity[103]. Simultaneously, CAFs can produce 
chemokines that promote the recruitment of effector T cells and natural killer cells, 
including CXCL9, CXCL10, and CXCL12[103]. If the latter chemokines are the 
predominant chemokines produced by CAFs, they can enhance specific tumor 
immunity instead of suppressing it. Indeed, depletion of CAFs induces 
immunosuppression and accelerates pancreas cancer progression with reduced 
survival in a mouse pancreatic ductal adenocarcinoma (PDAC) model[11]. This 
immunosuppression is associated with increased Foxp3-positive Treg cells and can 
be reversed by immune checkpoint therapy using the anti-CTLA4 antibody. Thus, 
in this model, CAFs prevent Tregs from expansion to keep tumor cells under 
immune surveillance. 
 
CAFS AS A PROGNOSIS MARKER IN CRC 
CAFs can be a useful marker to predict disease recurrence in patients with various 
types of cancer[10]. Tumors with abundant α-SMA-positive CAFs are associated 
with shorter disease-free survival for stage II and III CRC after curative CRC 
surgery[104]. High intra-tumor stroma proportion was associated with shorter 
overall survival and disease-free survival in stage II and stage III CRC patients 
after curative surgery[105]. CAFs abundantly express FAP-α and SDF-1/CXCL12. 
Colon cancer patients with high intra-tumor stromal FAP-α expression tend to 
have more aggressive disease progression and experience metastasis or 
recurrence[106]. Similarly, intra-tumor FAP-α and SDF-1 expression is involved in 
tumor re-growth and recurrence in rectal cancer patients treated with 
pre-operative chemo-radiation therapy[107]. 
Analysis of CAFs established from primary human colon cancer revealed that 
CAFs exhibit significant differences in their pro-migratory effects on cancer cells 
upon co-culture with cancer cells[33]. Moreover, CAFs promigratory effects on 
cancer cells are associated with fibroblast activation and stemness markers. CAF 
signature is identified by the gene expression signature of the most 
pro-tumorigenic CAFs and shows remarkable prognostic value for patients with 
CRC. Berdiel-Acer and colleagues conducted a transcriptomic profile of normal 
colonic fibroblasts (NCFs), primary tumor CAFs, and liver metastasis site CAFs, 
and identified a 19-gene classifier. In patients with CRC, this 19-gene classifier can 
predict recurrence with high accuracy, and correlates with fibroblast migratory 
potential[108]. Moreover, this 19-gene classifier can accurately identify low-risk 
patients, which is of particular importance for stage II patients. T4N0 patients, 
clinically classified as high risk, would particularly benefit from this prognostic 
tool and subsequent omission of chemotherapy. The same group further 
developed a 5-gene classifier for relapse prediction in Stage II/III CRC by 
analyzing gene expression patterns in CAFs[109]. The 5-gene classifier in CAFs was 
significantly associated with increased relapse risk and death from CRC among 
stage II/III patients. These studies proved the existence of heterogeneity in CAFs 
in terms of gene expression signatures. 
Molecular classification of CRC based on global gene expression profiles has 
defined three subtypes: chromosomal-instable tumor (CCS1), 
microsatellite-instable (MSI)/CpG island methylator (CIMP)-positive tumor 
(CCS2), and microsatellite-stable/CIMP-positive tumor (CCS3)[110]. The CCS3 
subtype exhibits upregulation of genes involved in matrix remodeling and EMT 
and has a very poor prognosis. However, more detailed analysis of the subgroups 
revealed that the prognostic predictive power arises from genes expressed by 
stromal cells rather than epithelial tumor cells[111]. Functional studies indicate that 
CAFs can increase the frequency of tumor-initiating cells and that this enhancing 
effect is further augmented by TGF-β signaling. Furthermore, poor-prognosis CRC 
displays a gene expression program induced by TGF-β in tumor stromal cells. 
These observations indicate that CAF-mediated gene expression profiles can be 
used to predict the prognosis of colon cancer patients. 
 
CAF AS A TARGET FOR CANCER TREATMENT 
Kraman and colleagues demonstrated that genetic depletion of FAP-expressing 
cells causes rapid hypoxic necrosis of both cancer and stromal cells in Lewis lung 
carcinoma-bearing mice depending on interferon (IFN)-γ and TNF-α. In addition, 
they demonstrated that depletion of FAP-expressing cells allows immunological 
tumors control[28]. However, the same group demonstrated that the FAP-positive 
cells of skeletal muscle are the major local source of follistatin and those in bone 
marrow express CXCL12 and kit ligand. Consequently, experimental ablation of 
these cells causes loss of muscle mass and a reduction of B-lymphopoiesis and 
erythropoiesis[29]. Thus, it is probable that depletion of FAP-positive cells in tumor 
tissue can cause cachexia and anemia, and therefore, it may be difficult to target 
FAP to deplete CAFs. 
We demonstrated the crucial involvement of the CCL3-CCR5 axis on 
AOM/DSS-induced colon carcinogenesis through recruiting and activating CAFs. 
Systemic delivery of a CCR5-antagonist-expressing vector is well tolerated by 
tumor-bearing mice and significantly reduces tumor mass together with decreased 
CAFs, even when it is given after multiple tumors develop[22]. An antagonist to the 
chemokine, CXCL12, inhibits CAF-mediated integrin β1 clustering at the cell 
surface and the invasive ability of gastric cancer cells, suggesting that the 
inhibition of CXCL12/CXCR4 signaling in gastric cancer cells may be a promising 
therapeutic strategy against gastric cell invasion[112]. Moreover, CAF-derived 
CXCL12 can provide prostate cancer cells with chemoresistance to the cytotoxic 
drug, docetaxel, and a CXCR4 antagonist can sensitize cancer cells to this drug in a 
subcutaneous xenograft model of prostate cancer[80]. PDAC-bearing mice 
frequently do not respond to immune checkpoint therapy with anti-programmed 
cell death ligand 1 (PD-L1) antibody despite the presence of tumor-specific 
CD8-positive cells. However, depletion of FAP-positive CAFs uncovers the 
antitumor effects of the anti-PD-L1 antibody and inhibits tumor growth[113]. 
FAP-positive CAFs express CXCL12; consequently, a CXCR4 antagonist also 
induces rapid T-cell accumulation among cancer cells acting synergistically with 
anti-PD-L1 to greatly diminish cancer cells in pancreatic cancer model[113]. 
Normalization of CAFs is proposed as the strategy targeting CAFs. In prostate 
cancer, CAFs exhibit reduced miR-15 and miR-16 expression associated with 
reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1[114]. The 
Fgf-2-Fgfr1 axis acts on both stromal and tumor cells to enhance cancer cell 
survival, proliferation, and migration. Moreover, reconstitution of miR-15 and 
miR-16 considerably impairs the tumor-supportive capability of stromal cells in 
vitro and in vivo[114]. In ovarian cancer CAFs downregulate miR-31 and miR-214 
and the expression of these miRNAs induces a functional conversion of CAFs into 
normal fibroblasts[115]. Similar observations were made of miR-31 and miR-148a 
expression in CAFs[116,117]. Phosphatase and tensin homolog deleted on 
chromosome 10 (Pten) expression in stromal fibroblasts suppresses epithelial 
mammary tumors. Pten-deficient mammary fibroblasts exhibit reduced miR-320 
expression, enhanced ETS2 expression, and can accelerate tumorigenicity when 
co-injected into mice with mouse mammary cancer cells[118]. miR-320 
overexpression in fibroblasts reduces their tumorigenic activity upon co-injection 
with cancer cells[118]. These observations indicate that the modulation of miRNA 
expression can reduce the pro-tumorigenic capacity of CAFs, by dedifferentiating 
CAFs into normal fibroblasts. 
Nintedanib is a broad-spectrum tyrosine kinase inhibitor targets the VEGF, FGF, 
and PDGF receptors binding to the ATP pocket in a competitively reversible 
manner. Nintedanib is used as monotherapy for the treatment of idiopathic lung 
fibrosis (IPF)[119] and reduces lung inflammation and fibrosis in IPF as seen by 
reduced deposition of type I collagen and inhibition of fibroblast activation. VEGF, 
FGF, and PDGF are secreted by CAFs, cancer cells, and TAMs and their receptors 
are expressed by CAFs, cancer cells, and endothelial cells[120]. Moreover, the 
mechanism of fibroblast activation in IPF closely resembles that in cancer[121]. 
Hence, nintedanib is proposed as a second line therapy for non-small cell lung 
cancer in combination with docetaxel[122]. Another anti-fibrotic agent, pirfenidone, 
is used to treat IPF although its exact molecular mechanisms remain unknown[123]. 
The combination of pirfenidone and cisplatin leads to increased CAF cell death and 
decreased tumor progression in a human non-small cell lung cancer xenografted 
model[124]. These observations indicate that these anti-fibrotic agents may be used 
for the treatment of cancers with abundant fibrotic changes. 
Given the potent fibrotic capacity of TGF-β[98], the anti-TGF-β monoclonal 
antibody was developed and tested in clinical trials for several cancer types. The 
anti-TGF-β antibody can simultaneously induce anti-tumor effects and cutaneous 
keratoacanthomas/squamous cell carcinomas[125]. This duplicity may arise from 
the double-edged activities of TGF-β; a tumor suppressor for normal epithelial 
cells and a tumor driver in tumor microenvironments[98]. 
 
FUTURE PERSPECTIVES 
Accumulating evidence highlights the crucial involvement of inflammation in 
cancer development and progression[12]. Inflammation is a dynamic host response, 
wherein various cell types participate in a concerted manner[4]. However, until 
recently, much attention has been focused on two processes involved in 
inflammation: neovascularization, and inflammatory cell infiltration. Various 
agents targeting neovascularization have been developed as anti-cancer drugs, 
with limited success[126]. Despite remarkable successes of immunotherapies that 
modulate the adaptive immune system consisting of lymphocytes and dendritic 
cells[127], the plasticity and heterogeneity of inflammatory leukocytes, 
monocytes/macrophages, and granulocytes has hindered the elucidation of their 
roles these in carcinogenesis. Likewise the development of anti-cancer agents 
targeting inflammatory leukocytes[128] has been equally hindered. Under these 
circumstances, fibroblasts, have emerged as an important player in cancer-related 
inflammation[10,25,129]. 
CAFs express an NF-ĸB-dependent gene signature in mouse skin, pancreatic and 
breast cancer models[86]. These observations incited two independent groups to 
conduct fibroblast-specific deletion of the gene of IKKβ, required for NF-ĸB 
activation, and examine the effects on AOM/DSS-induced colon 
carcinogenesis[130,131]. However, the results obtained from the two studies are 
completely opposite to each other. Koliaraki and colleagues demonstrated a 
pro-tumorigenic activity of IKKβ whilst, Pallangyo identified IKKβ as a tumor 
suppressor. The differences observed by the two groups appear to arise from the 
use of different gene promoters to delete the IKKβ gene. Koliaraki and colleagues 
used the type VI collagen gene promoter whereas Pallangyo and colleagues used 
the type I collagen gene promoter. IKKβ deletion in type VI collagen-positive CAFs, 
decreased IL-6 production associated with decreased inflammation and 
suppressed tumor formation[130]. In contrast, IKKβ deletion in type I 
collagen-positive CAFs, enhanced HGF production and subsequently promoted 
tumor growth[131]. Therefore, in general, CAFs may act to promote carcinogenesis, 
but a type I collagen-positive subset may retain normal fibroblast-like phenotypes 
and functionality. This type I collagen-positive subset can act to suppress 
carcinogenesis, because normal intestinal fibroblasts can regulate intestinal 
homeostasis to suppress colitis-associated tumorigenesis[23]. 
Targeting CAFs can be a novel strategy to treat cancer, and inflammation-related 
cancer in particular. In order to advance this strategy, however, a more detailed 
and precise understanding of phenotypical and functional heterogeneity in CAFs is 
required to identify the CAF subpopulation and/or molecules, with crucial roles in 
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Table 1 Pathological changes in mice after azoxymethane/dextran sulfate sodium 
treatment 
















Wild-type mice 3.0 + + + > 20 
CCR1-deficient mice 3.0 - - - < 5 
 4.5 + + + > 20 
CCR5-deficient mice 3.0 - - - < 5 
 4.5 + + - < 7 
CCL3-deficient mice 3.0 - - - < 5 
 4.5 + + - < 5 
 




Figure 1 The origin of CAFs. A variety of cells can become CAFs. The most 
important cellular source of CAFs in CRC is presumed to be resident fibroblasts. 
Stellate cells in the intestine may be able to transform into CAFs in a manner 
similar to what occurs in the liver and pancreas. Other potential sources include 
epithelial cells undergoing EMT, endothelial cells undergoing EndoMT, smooth 
muscle cells, and bone marrow-derived cells including fibrocytes and MSCs. CAFs: 
Cancer associated fibroblasts; CRC: Colorectal cancer; EMT: 
Epithelial-mesenchymal transition; MSCs: mesenchymal stem cells. 
 
Figure 2 The action of CAFs on tumor cells. CAFs can induce tumor cells to 
enhance their tumor initiating capacity (stemness), and to undergo EMT. CAFs 
provide tumor cells with various growth factors to promote their growth. CAFs 
can also instigate a pro-metastatic niche by inducing tumor cell cluster and 
angiogenesis, and suppressing tumor cell apoptosis. CAFs: Cancer associated 
fibroblasts; EMT: Epithelial-mesenchymal transition; VEGF: Vascular endothelial 
growth factor. 
 
Figure 3 Cancer associated fibroblasts in tumor microenvironment formation. 
CAFs promote pro-tumorigenic microenvironment by: producing extracellular 
matrix to provide tumor cells with a growth advantage, recruiting 
tumor-associated macrophages (TAMs) to foster tumor cell growth, and by 
inducing neovascularization. CAFs: Cancer associated fibroblasts; EMT: 
Epithelial-mesenchymal transition; VEGF: Vascular endothelial growth factor; 
ECM: Extracellular matrix proteins; EPCs: Endothelial progenitor cells; MMP: 
Matrix metalloproteinase; HIF-1α: Hypoxia-inducible factor 1α. 
 
Figure 4 Double-edged actions of cancer associated fibroblasts in tumor 
immunity. CAFs exhibit double-edged actions in tumor immunity. In most cancer 
types, CAFs can dampen tumor immunity by suppressing T cell proliferation, NK 
cell activity, DC maturation, and by inducing Treg proliferation and MDSC 
accumulation. In some types of cancers, such as pancreatic ductal adenocarcinoma, 
CAFs can enhance tumor immunity by enhancing effector T cell and NK cell 
functions and depressing Treg activities. CAFs: Cancer associated fibroblasts; 
VEGF: Vascular endothelial growth factor; MDSC: Myeloid-derived suppressor 




Figure 1. The origin of cancer-associated fibroblasts (CAFs) 
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Figure 2. CAFs promote tumor proliferation, and maintain cancer cell stemness and migratory capacity 
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Figure 4. CAFs regulate tumor immunity 
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• Pancreatic ductal adenocarcinoma • Hepatocellular carcinoma 
• Prostate cancer 
• Colorectal cancer 
